Use of gemcitabine in non-small-cell lung cancer

Current Oncology

Volumn 10, Issue 1, 2003, Pages 3-26

  Ellis, P ^b   Mackay, J A ^b   Evans, W K ^a  

^a CANCER CARE ONTARIO   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL;

ADVANCED CANCER; ALOPECIA; ANEMIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HEMOPTYSIS; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0038393117     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-12.
2. Evans WK, Kocha W, Gagliardi A, Eady A, Newman TE. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic-Treatment Disease Site Group. Cancer Prev Control 1999;3:84-94.
3. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) VS. BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 2000;83:447-53.
4. Vansteenkiste J, Vandebroek J, Nackaerts K, et al. Symptom control in advanced non-small cell lung cancer (NSCLC): a multicenter prospective randomised phase III study of single agent gemcitabine (GEM) versus cisplatin-vindesine (PV) [abstract]. Proc Am Soc Clin Oncol 2000;19:488a.
5. ten Bokkel Huinink WW, Bergman B, Chemaissani A, et al. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer 1999;26:85-94.
6. Perng RP, Chen YM, Ming-Liu J, et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 1997;15:2097-102.
7. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
8. Vokes EE. Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer. Oncologist 2001;6(suppl 1):25-7.
9. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-30.
10. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomised phase III study of gemcitabine-cisplatin versus etoposidecisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:12-18.
11. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999;17:3522-30.
12. Berardi R, Porfiri E, Massidda B, et al. Gemcitabine (GEM) and cisplatin (PL) versus gemcitabine alone in stage IV non small cell lung cancer (NSCLC): preliminary results of a randomized multicenter phase III study [abstract]. Proc Am Soc Clin Oncol 2001;20:347a.
13. Chang JWC, Liaw CC, Chen CH, Yang CT, Lin MC, Tsao TCY. Randomized phase II study of vinorelbine plus cisplatinum versus gemcitabine plus cisplatinum in advanced non-small cell lung cancer: a preliminary result [abstract]. Proc Am Soc Clin Oncol 2001;20:336a.
14. Cicenas S, Pipiriene T, Burneckis A, Ciceniene A, Wein W. Gemcitabine-cisplatin (GC) versus etoposide-cisplatin (EC) in patients with inoperable stage IIIA/IIIB non-small cell lung cancer (NSCLC) with intermittent radiotherapy: a randomized phase II trial [abstract]. Proc Am Soc Clin Oncol 2001;20:270b.
15. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2001;20:308a.
16. van Meerbeeck JP, Smit EF, Lianes P, et al. An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2001;20:308a.
17. Danson S, Clemons M, Middleton M, et al. A randomised study of gemcitabine with carboplatin (GC) versus mitomycin, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small-cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2001;20:322a.
18. Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients (pts) with non-small cell lung cancer (NSCLC) stage IIIb and IV: An interim analysis of a randomized trial [abstract]. Proc Am Soc Clin Oncol 2001;20:337a.
19. Mazzanti P, Lippe P, Battelli N, et al. Gemcitabine-cisplatin (GP) vs. gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (ANSCLC): a multicenter phase II randomized trial of a 21-day schedule. Preliminary results [abstract]. Proc Am Soc Clin Oncol 2000;19:540a.
20. Ricci S, Antonuzzo A, Galli L, et al. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma. Cancer 2000;89:1714-19.
21. Rinaldi M, Crino L, Scagliotti GV, et al. A three-week sched- ule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann Oncol 2000;11:1295-300.
22. Comella P. Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small-cell lung cancer. Semin Oncol 2001;28(suppl 7):7-10.
23. Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000;18:1451-7.
24. Comella P, Frasci G, Panza N, et al. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol 1999; 17:1526-34.
25. Alberola V, Camps C, Provencia M, et al. Cisplatin/gemcitabine (CG) vs. cisplatin/gemcitabine/vinorelbine (CGV) VS. sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer (NSCLC): results of a Spanish Lung Cancer Group phase III trial (GEPC/98-02) [abstract]. Proc Am Soc Clin Oncol 2001;20:308a.
26. Edelman MJ, Clark JI, Chansky K, Crowley J, Albain K, Gandara DR. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine (CARB/G) followed by paclitaxel (P) or cisplatin/vinorelbine (C/V) followed by docetaxel (D) [abstract]. Proc Am Soc Clin Oncol 2001;20:314a.
27. Thompson DS, Hainsworth JD, Burris HAI, et al. Prospective randomized study of four third generation chemotherapy regimens in patients (pts) with advanced non-small cell lung cancer: a Minnie Pearl Cancer Research Network trial [abstract]. Proc Am Soc Clin Oncol 2001;20:314a.
28. Hussein A, Birch R, Waller J, et al. Preliminary results of a randomized study comparing paclitaxel and carboplatin (PC) with or without gemcitabine (G) in newly diagnosed non small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2000;19:504a.
29. Chen YM, Perng RP, Lee YC, et al. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 2002; 13:108-15.
30. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001;357:1478-84.
31. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:2529-36.
32. Kosmidis PA, Bacoyiannis C, Mylonakis N, et al. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non small cell lung cancer (NSCLC). A preliminary analysis [abstract]. Proc Am Clin Oncol 2000;19:488a.
33. Gillenwater HH, Tynan M, Natoli S, Schell MJ, Socinski MA. Second-line gemcitabine in refractory stage IV non-small-cell lung cancer: a phase II trial. Clin Lung Cancer 2000;2:133-8.
34. Sculier JP, Lafitte JJ, Berghmans T, et al. A phase II trial testing gemcitabine as second-line chemotherapy for non-small cell lung cancer. Lung Cancer 2000;29:67-73.
35. Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1999;17:2081-5.
36. Gridelli C, Perrone F, Gallo C, et al. Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial. Anticancer Res 1999; 19:4535-8.
37. Hainsworth JD, Burris HA, Billings FT, Bradof JE, Baker M, Greco FA. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced non-small cell lung carcinoma. Phase II trials of the Minnie Pearl Cancer Research Network. Cancer 2001;92:2391-8.
38. Kakolyris S, Papadakis E, Tsiafaki X, et al. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Lung Cancer 2001;32:179-87.
39. Kosmas C, Tsavaris N, Vadiaka M, et al. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 2001;92:2902-10.
40. Spiridonidis CH, Laufman LR, Carman L, et al. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. Ann Oncol 2001;12:89-94.
41. Rosati G, Rossi A, Nicolella G, Panza N. Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer. Anticancer Res 2000;20:2229-33.
42. Androulakis N, Kouroussis C, Kakolyris S, et al. Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. Ann Oncol 1998; 9:1127-30.
43. Kosmas C, Tsavaris N, Panopoulos C, et al. Gemcitabine and vinorelbine as second-line therapy in non-small cell lung cancer after prior treatment with taxane+platinum-based regimens. Eur J Cancer 2001;37:972-8.
44. Pectasides D, Kalofonos HP, Samantas E, et al. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic Co-operative Oncology Group. Anticancer Res 2001; 21:3005-10.
45. Hainsworth JD, Burris HA, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a Minnie Pearl Cancer Research Network phase II trial. Cancer 2000;88:1353-8.
46. Frasci G, Panza N, Comella P, et al. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group. J Clin Oncol 1999;17:2316-25.
47. Georgoulias V, Kourousis C, Kakolyris S, et al. Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen. Semin Oncol 1997;24(suppl 12):S12-61-S12-66.
48. Curran WJ Jr, Choy H. Optimizing chemoradiation in locally advanced non-small-cell lung cancer. Oncology (Huntingt) 2001;15(suppl 6):43-5.
49. Gridelli C, Perrone F, Cigolari S, et al. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: gemcitabine + vinorelbine vs. vinorelbine and vs. gemcitabine in elderly advanced NSCLC patients [abstract]. Proc Am Soc Clin Oncol 2001;20:308a.